Library · Reproductive · Treatment of hypoactive sexual desire disorder
PT-141 (Bremelanotide / Vyleesi)
PT-141, Vyleesi, PT141
Also called Bremelanotide (Vyleesi), this melanocortin receptor agonist developed from Melanotan II gained FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women, only the second approved drug for that condition, and works through the brain rather than blood flow.
Research score 90/100. Reference only, not a dose.
- Libido Enhancement
- Hormone Regulation
- Melanocortin Agonist
- Mood Enhancement
- Erectile Function
- US status
- FDA Approved
- Approval
- FDA Approved
- Evidence
- FDA approved for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Effective melanocortin receptor agonist.
- Research score
- 90 / 100
- Indication
- Female Sexual Dysfunction
- Origin
- USA
- Source category
- Reproductive System
- Status group
- Approved / prescription
Mechanism
Selectively activates MC4R in the central nervous system, engaging G-protein signaling that raises cAMP and PKA activity, altering neurotransmitter release in the hypothalamus and limbic system to boost sexual motivation via dopaminergic and adrenergic pathways.
Safety file
Nausea is very common, around 40%; flushing and headache occur; transient blood pressure rises can occur; frequent use risks permanent focal hyperpigmentation.
- Nausea
- Flushing
- Injection site reactions
- Headache
- Vomiting
- Temporary blood pressure elevation